ObsEva
Chemin des Aulx, 12
1228 Plan-les-Ouates
Geneva
Website: http://www.obseva.com/
Email: delphine.renaud@obseva.ch
97 articles about ObsEva
-
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF
8/4/2021
ObsEva SA announced the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization.
-
ObsEva to Present at Upcoming Investor Conferences - Aug 03, 2021
8/3/2021
ObsEva SA announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Conference to be held August 10-11, 2021 and the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
-
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
7/27/2021
Organon, a global women’s health company and ObsEva, a biopharmaceutical company dedicated to improving women’s reproductive health, announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant.
-
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
7/2/2021
ObsEva SA announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation 68th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.
-
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
6/30/2021
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced clinical data from a pilot study on Yselty® for the treatment of severe adenomyosis was presented at the European Society of Human Reproduction and Embryology Virtual 37th Annual Meeting, being held June 26-July 1, 2021.
-
ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
6/24/2021
ObsEva SA announced the presentation of data from two of its clinical development programs at the European Society of Human Reproduction and Embryology Virtual 37th Annual Meeting, being held June 26 - July 1, 2021.
-
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
6/10/2021
ObsEva SA announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant for the treatment of spontaneous preterm labor at the Royal College of Obstetricians and Gynecologists Virtual World Congress 2021.
-
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
6/2/2021
Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation
-
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021
5/31/2021
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that shareholders approved all Board proposals at its 2021 Annual General Meeting held on May 28, 2021.
-
ObsEva Announces Proposed Changes to the Composition of its Board of Directors
5/25/2021
ObsEva SA announced that its Board of Directors will propose the election at the 2021 Annual General Meeting of Shareholders to be held on May 28, 2021 of Anne VanLent as member of the Board of Directors for a term of one year expiring at the closing of the 2022 Annual General Meeting of Shareholders.
-
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
5/20/2021
PRIMROSE 1 76-week results confirmPRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment
-
ObsEva appoints Clive Bertram as Chief Commercial Officer
5/6/2021
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced the appointment of Clive Bertram as Chief Commercial Officer and member of ObsEva’s Executive Committee, effective May 10, 2021.
-
ObsEva Announces First Quarter 2021 Financial Results and Business Update
5/6/2021
Yselty® for uterine fibroids: US New Drug Application submissionplanned in Q3:21; European marketing approval recommendation anticipated in Q4:21
-
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
5/4/2021
EDELWEISS 3trial of Yselty® expected to report topline data as plannedin Q4:21
-
Clinical Catch-Up: July 6-10
7/13/2020
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates. -
ObsEva, based in Geneva, Switzerland and Boston, Massachusetts, announced topline data from the PRIMROSE 1 and 2 Phase III trials of Yselty (linzagolix) for uterine fibroids.
-
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12/9/2019
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, reported positive Phase 3 trial results from the PRIMROSE 2 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids.
-
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
10/31/2019
ObsEva SA announced that the U.S. Food and Drug Administration has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer following in-vitro fertilization.
-
BioSpace Movers and Shakers: July 3
7/3/2019
Biotech and pharma companies strengthen their executive leadership and board positions.